We started Curiomed because the people we love kept getting bad information at the worst possible moments. Friends in the middle of a cancer diagnosis, parents staring at a 30-page hospital quote, family members trying to weigh four destinations on a group chat at 2am.
In every case, the information existed somewhere. It was just spread across forums, marketing sites, friend-of-a-friend recommendations, and a handful of doctors who happened to pick up the phone. No one had put it together with a patient's actual decision in mind.
So we did. Curiomed is the team and the system that does that work — for every condition, every destination, every realistic budget, updated weekly. Not a hospital. Not a broker. Not an insurance product. A clear-eyed second brain for cross-border medical decisions.
Stated plainly so you can disagree with us before you read further.
The cross-border medical decision is one of the highest-stakes choices most families ever make, and it is structurally under-served. The hospitals that are best at marketing are not always the hospitals that are best at medicine, and the gap between those two facts is where many families need to identify risk before they commit to a path.
The traditional model — a broker, an agency, a "patient coordinator" — can be shaped by the wrong incentive: recommend the destination with the strongest commercial relationship. Most people doing this work are decent. The model still needs tighter safeguards because patients cannot easily see whose interest is being served.
The alternative is straightforward to describe and difficult to execute. Build a structured knowledge system. Hire people whose incentives are aligned with the patient. Publish the limitations — including the cases where the answer is "don't come, stay home." Make money from the patients we actually help, not the hospitals we route people to.
Curiomed is the team trying to execute that alternative. We are early. We are not big. We are honest about the parts we are still figuring out — and the parts where the industry needs to change faster than we can pull it.
In the cross-border medical space, neutral is not honest. So we don't pretend to be.
$200–$2000 for a credentialed review can change downstream decisions in complex cases. For high-risk, high-cost, or conflicting recommendations, it should usually be considered early.
For many elective procedures, the surgeon's recent case volume is an important signal. It still needs to be interpreted against the condition, procedure, and patient context.
Some inquirers will be told that cross-border care is not the right call for them. That is not a failure of the service; it is part of the boundary.
Used to organize information, frame questions, and surface patterns — AI helps. Used to give a diagnosis or a treatment plan — it doesn't.
A famous hospital with the wrong specialist for your case underperforms an unfamous hospital with the right one. Every time. We have stopped being polite about this.
It is occasionally true. The headline savings number consistently underweights travel, follow-up, complications, and the things insurance won't cover. We've yet to find an exception worth the trip.
Across 43 clinics we have reviewed, we recommend zero. We may change our minds when the regulatory landscape changes. So far, it has not.
A nicer room, faster check-in, an English-speaking concierge. These are real services with real costs. They do not change the medicine. We will tell you when they are worth it — which is rarely.
8 in operating team, 6 medical advisors across 4 regions. Every name on this page is a real person who actually reviews real cases.
If we don't draw the line, the industry will draw it badly. So we do.
As of March 2026. Stated honestly — small in some places, growing in others.
The review process focuses on medical accuracy, risk boundaries, and restrained wording. Specific advisor identities will be published after authorization is complete.
High-stakes oncology content enters medical review; reviewers focus on accuracy, risk boundaries, and suitability signals, not treatment decisions.
Cardiac and cardiothoracic content enters medical review; review focuses on indications, complications, wait time, and follow-up boundaries.
Spine and orthopedic content enters medical review; review focuses on procedure suitability, rehabilitation, and cross-border follow-up conditions.
Breast oncology content enters medical review; review focuses on staging, treatment goals, reconstruction choices, and cost risk.
We answer everything we get within 48h. If you have a specific medical situation, please don't write the details in a first email — we'll route you to a proper intake. The general inbox below is for everything else.